Src蛋白酪氨酸激酶抑制剂在骨质疏松症中的研究进展  

Research Progress of the Treatment on Osteoporotic Disease with Src Protein Tyrosine Kinase Inhibitor

作　　者：刘宝成 屈孝东 常彦海[2] 杨波[2] 

机构地区：[1]西安医学院,陕西 西安 [2]陕西省人民医院,陕西 西安

出　　处：《临床医学进展》2022年第5期3827-3833,共7页Advances in Clinical Medicine

摘　　要：骨质破坏发生在衰老和许多疾病中,其中最常见的是骨质疏松。骨质疏松症(Osteoporosis, OP)是中国中老年患者最常见且发病率高的全身代谢性骨病,其发生是多种因素造成人体骨密度及骨质量下降,骨骼微小结构破坏,骨骼易脆性增高,导致老年人更容易在日常活动中发生骨折。Src蛋白酪氨酸激酶抑制剂能够抑制Src蛋白酪氨酸激酶活性,对于骨质疏松的靶向治疗具有精准、稳定性强、副作用小,可直接进入病灶、无明显毒副作用等特点。本文就Src蛋白酪氨酸激酶抑制剂在骨质疏松症中的研究进展做一综述。Bone destruction occurs with aging and in many diseases, the most common of which is osteoporo-sis. Osteoporosis (OP) is a kind of systemic metabolic bone disease with high incidence as a common disease in middle-aged and elderly patients in China. Its occurrence is caused by a variety of factors resulting in the reduction of bone density and bone mass of the human body, the destruction of bone micro-structure, resulting in increased brittleness of the bone, resulting in the elderly more prone to fracture in daily activities. Src protein tyrosine kinase inhibitor can inhibit the activity of Src protein tyrosine kinase. It has the characteristics of precision, low side effects, strong stability, direct access to the focus and no obvious toxic and side effects for the targeted treatment of osteo-porosis. Now we review the research progress of SRC protein tyrosine kinase inhibitors in the treatment of osteoporosis.

关 键 词：Src蛋白酪氨酸激酶 骨质疏松症 Src蛋白酪氨酸激酶抑制剂 

分 类 号：R681[医药卫生—骨科学]